Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | Venetoclax for elderly AML patients

Mark Levis • 5 Oct 2017
ESH 2017
Acute Myeloid Leukemia Venetoclax

The BCL2 inhibitor venetoclax has shown remarkable response rates in elderly acute myeloid leukemia (AML) patients when used in combination regimens. Speaking at the International Conference on Acute Myeloid Leukemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), Mark Levis, MD, PhD, from The Johns Hopkins Hospital, Baltimore, MD, discusses how this, along with allogenic transplantation, has changed the way in which elderly AML patients are now being treated.

More from Mark Levis

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:03
Personalizing AML treatment by targeting MRD mutations
Mark Levis • 10 Dec 2023
2:00
FLT3-ITD-specific MRD predicts outcomes of chemotherapy in AML
Mark Levis • 10 Dec 2023

Related Videos

1:49
Exciting therapeutic approaches in the AML space
Steven Knapper • 1 May 2024
4:16
The novel bioactive peptide QUB-2392 shows anti-leukemic effects in leukemia cell lines
Ruth Gyereh • 28 Apr 2024
2:04
Increasing awareness of germline predispositions to hematological malignancies in pediatric patients
Anupama Rao • 29 Apr 2024
0:57
The development of a UK AML registry
Priyanka Mehta • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals